New membranes for extracorporeal blood purification in septic conditions

Minerva Anestesiologica

Volumn 78, Issue 11, 2012, Pages 1265-1281

  Bello, G ^a   Di Muzio, F ^a   Maviglia, R ^a   Antonelli, M ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Inflammation mediators; Membranes, artificial; Renal replacement therapy; Sepsis

Indexed keywords

ADSORBENT; CENTOXIN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; PLACEBO; POLY (METHYL METHACRYLATE); POLYACRYLONITRILE; POLYAMIDE; POLYMYXIN B; POLYSULFONE; TEICOPLANIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

BLEEDING; BRAIN EDEMA; CARDIOGENIC SHOCK; CONTINUOUS RENAL REPLACEMENT THERAPY; DIALYSIS MEMBRANE; HEART ARREST; HEART ARRHYTHMIA; HEMADSORPTION; HEMODIALYSIS; HEMODIALYSIS MACHINE; HEMOPERFUSION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXEMIA; INFLAMMATION; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; ULTRAFILTRATION;

ADSORPTION; FILTRATION; HEMOFILTRATION; HUMANS; INFLAMMATION MEDIATORS; MEMBRANES, ARTIFICIAL; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 84871322617     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H et al. Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344-53.
3. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991;115:457-69.
4. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001;16:83-96.
5. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1829-35.
6. Honoré PM, Joannes-Boyau O, Boer W, Collin V. Highvolume hemofiltration in sepsis and SIRS: current concepts and future prospects. Blood Purif 2009;28:1-11.
7. Kellum JA, Ronco C. Dialysis: Results of RENAL 2011; what is the optimal CRRT target dose? Nat Rev Nephrol 2010;6:191-2.
8. Impact of High-volume veno-venous continuous hemofiltration in the early management of septic shock patients with acute renal failure. [cited 2012 October 5]. Available at: http://clinicaltrials.gov/ct2/show/NCT00241228
9. Kellum JA, Mehta RL, Angus DC, Palevsky P, Ronco C. The first international consensus conference on continuous renal replacement therapy. Kidney Int 2002;62:1855-63.
10. De Vriese AS, Vanholder RC, Pascual M, Lameire NH, Colardyn FA. Can inflammatory cytokines be removed efficiently by continuous renal replacement therapies? Intensive Care Med 1999;25:903-10.
11. Kellum JA, Johnson JP, Kramer D, Palevsky P, Brady JJ, Pinsky MR. Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome. Crit Care Med 1998;26:1995-2000.
12. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002;30:100-6.
13. Toft P, Nilsen BU, Bollen P, Lillevang S, Olsen KE, Brøchner AC et al. The impact of long-term haemofiltration (continuous veno-venous haemofiltration) on cell-mediated immunity during endotoxaemia. Acta Anaesthesiol Scand 2007;51:679-86.
14. De Vriese AS, Colardyn FA, Philippé JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846-53.
15. Pascual M, Tolkoff-Rubin N, Schifferli JA. Is adsorption an important characteristic of dialysis membranes? Kidney Int 1996;49:309-13.
16. Bellomo R, Tipping P, Boyce N. Continuous veno-venous hemofiltration with dialysis removes cytokines from the circulation of septic patients. Crit Care Med 1993;21:522-6.
17. Bellomo R, Tipping P, Boyce N. Interleukin-6 and interleukin- 8 extraction during continuous venovenous hemodiafiltration in septic acute renal failure. Ren Fail 1995;17:457-66.
18. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med 1997;23:878-84.
19. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P. High-volume haemofiltration in human septic shock. Intensive Care Med 2001;27:978-86.
20. Klouche K, Cavadore P, Portales P, Clot J, Canaud B, Béraud JJ. Continuous veno-venous hemofiltration improves hemodynamics in septic shock with acute renal failure without modifying TNFalpha and IL6 plasma concentrations. J Nephrol 2002;15:150-7.
21. Rogiers P, Zhang H, Pauwels D, Vincent JL. Comparison of polyacrylonitrile (AN69) and polysulphone membrane during hemofiltration in canine endotoxic shock. Crit Care Med 2003;31:1219-25.
22. Jiang HL, Xue WJ, Li DQ, Yin AP, Xin X, Li CM et al. Influence of continuous veno-venous hemofiltration on the course of acute pancreatitis. World J Gastroenterol 2005;11:4815-21.
23. Rimmelé T, Assadi A, Cattenoz M, Desebbe O, Lambert C, Boselli E et al. High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 2009;24:421-7.
24. Taniguchi T, Hirai F, Takemoto Y, Tsuda K, Yamamoto K, Inaba H et al. A novel adsorbent of circulating bacterial toxins and cytokines: the effect of direct hemoperfusion with CTR column for the treatment of experimental endotoxemia. Crit Care Med 2006;34:800-6.
25. Taniguchi T, Kurita A, Mukawa C, Yamamoto K, Inaba H. Dose-related effects of direct hemoperfusion using a cytokine adsorbent column for the treatment of experimental endotoxemia. Intensive Care Med 2007;33:529-33.
26. Kellum JA, Song M, Venkataraman R. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004;32:801-5.
27. Peng ZY, Carter MJ, Kellum JA. Effects of hemoadsorption on cytokine removal and short-term survival in septic rats. Crit Care Med 2008;36:1573-7.
28. Peng ZY, Wang HZ, Carter MJ, Dileo MV, Bishop JV, Zhou FH et al. Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int 2012;81:363-9.
29. Morgera S, Haase M, Rocktäschel J, Böhler T, von Heymann C, Vargas-Hein O et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant 2003;18:2570-6.
30. Morgera S, Haase M, Rocktäschel J, Böhler T, Vargas-Hein O, Melzer C et al. Intermittent high-permeability hemofiltration modulates inflammatory response in septic patients with multiorgan failure. Nephron Clin Pract 2003;94:c75-80.
31. Morgera S, Rocktäschel J, Haase M, Lehmann C, von Heymann C, Ziemer S et al. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med 2003;29:1989-95.
32. Nakada TA, Oda S, Matsuda K, Sadahiro T, Nakamura M, Abe R et al. Continuous hemodiafiltration with PMMA Hemofilter in the treatment of patients with septic shock. Mol Med 2008;14:257-63.
33. Nishida O, Nakamura T, Kuriyama N, Hara Y, Yumoto M, Shimomura Y et al. Sustained high-efficiency daily diafiltration using a mediator-adsorbing membrane (SHEDD-fA) in the treatment of patients with severe sepsis. Contrib Nephrol 2011;173:172-81.
34. Tani T, Hanasawa K, Kodama M, Imaizumi H, Yonekawa M, Saito M et al. Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 activities in septic patients. World J Surg 2001;25:660-8.
35. Suzuki H, Nemoto H, Nakamoto H, Okada H, Sugahara S, Kanno Y et al. Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther Apher 2002;6:234-40.
36. Nakamura T, Ushiyama C, Suzuki Y, Osada S, Inoue T, Shoji H et al. Hemoperfusion with Polymyxin B-Immobilized Fiber in Septic Patients with Methicillin-Resistant Staphylococcus aureus-Associated Glomerulonephritis. Nephron Clin Pract 2003;94:c33-c39.
37. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005;23:400-5.
38. Kushi H, Miki T, Okamaoto K, Nakahara J, Saito T, Tanjoh K. Early hemoperfusion with an immobilized polymyxin B fiber column eliminates humoral mediators and improves pulmonary oxygenation. Crit Care 2005;9:R653-61.
39. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-52.
40. Heering P, Morgera S, Schmitz FJ, Schmitz G, Willers R, Schultheiss HP et al. Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 1997;23:288-96.
41. Rogiers P, Zhang H, Smail N, Pauwels D, Vincent JL. Continuous venovenous hemofiltration improves cardiac performance by mechanisms other than tumor necrosis factoralpha attenuation during endotoxic shock. Crit Care Med 1999;27:1848-55.
42. Honoré PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B et al. Prospective evaluation of short-term, highvolume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581-7.
43. Cornejo R, Downey P, Castro R, Romero C, Regueira T, Vega J et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 2006;32:713-22.
44. Piccinni P, Dan M, Barbacini S, Carraro R, Lieta E, Marafon S et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med 2006;32:80-6.
45. Boussekey N, Chiche A, Faure K, Devos P, Guery B, d'Escrivan T et al. A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med 2008;34:1646-53.
46. Zhu Y, Zhang P, Yuan J, He Q, Jiang H, Hu X et al. Adjunctive continuous high-volume hemofiltration in acute severe pancreatitis patients: a retrospective study. Scand J Gastroenterol 2009;44:1363-9.
47. Zhu Y, Yuan J, Zhang P, Hu X, He Q, Han F et al. Adjunctive continuous high-volume hemofiltration in patients with acute severe pancreatitis: a prospective nonrandomized study. Pancreas 2011;40:109-13.
48. Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27:792-801.
49. Honoré PM, Matson JR. Extracorporeal removal for sepsis: Acting at the tissue level--the beginning of a new era for this treatment modality in septic shock. Crit Care Med 2004;32:896-7.
50. Di Carlo JV, Alexander SR. Hemofiltration for cytokinedriven illnesses: the mediator delivery hypothesis. Int J Artif Organs 2005;28:777-86.
51. Peng Z, Singbartl K, Simon P, Rimmelé T, Bishop J, Clermont G et al. Blood purification in sepsis: a new paradigm. Contrib Nephrol 2010;165:322-8.
52. Ono S, Tsujimoto H, Matsumoto A, Ikuta S, Kinoshita M, Mochizuki H. Modulation of human leukocyte antigen- DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin Bimmobilized fiber. Am J Surg 2004;188:150-6.
53. Ziegler EJ, Fisher CJ, Jr., Sprung CL, Straube RC, Sadoff JC, Foulke GE et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebocontrolled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324:429-36.
54. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin. Arch Intern Med 1994;154:2484-91.
55. Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001;29:765-9.
56. Yatzidis H. A convenient hemoperfusion micro-apparatus over charcoal for the treatment of endogenous and exogenous intoxications. Its use as an effective artificial kidney. Proc Eur Dial Transpl Assoc 1964;1:83-87.
57. Tsuchida K, Takemoto Y, Nakamura T, Fu O, Okada C, Yamagami S et al. Lixelle adsorbent to remove inflammatory cytokines. Artif Organs 1998;22:1064-7.
58. Cohen J, Aslam M, Pusey CD, Ryan CJ. Protection from endotoxemia: a rat model of plasmapheresis and specific adsorption with polymyxin B. J Infect Dis 1987;155:690-5.
59. Aoki H, Kodama M, Tani T, Hanasawa K. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994;167:412-7.
60. Kodama M, Tani T, Hanasawa K, Hirata K, Hirasawa H, Oda S et al. Treatment of sepsis by plasma endotoxin removal: hemoperfusion using a polymyxin-B immobilized column. Journal of Endotoxin Research 1997;4:293-300.
61. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007;11:R47.
62. Kellum JA, Uchino S: International differences in the treatment of sepsis: are they justified? JAMA 2009;301:2496-7.
63. Zagli G, Bonizzoli M, Spina R, Cianchi G, Pasquini A, Anichini V et al. Effects of hemoperfusion with an immobilized polymyxin-B fiber column on cytokine plasma levels in patients with abdominal sepsis. Minerva Anestesiol 2010;76:405-12.
64. Novelli G, Ferretti G, Ruberto F, Morabito V, Pugliese F. Early management of endotoxemia using the endotoxin activity assay and polymyxin B-based hemoperfusion. Contrib Nephrol 2010;167:91-101.
65. Martin EL, Cruz DN, Monti G, Casella G, Vesconi S, Ranieri VM et al. Endotoxin removal: how far from the evidence? The EUPHAS 2 Project. Contrib Nephrol 2010;167:119-25.
66. Rachoin JS, Foster D, Dellinger RP. Endotoxin removal: how far from the evidence? From EUPHAS to EUPHRATES. Contrib Nephrol 2010;167:111-8.
67. Effects of Hemoperfusion With a Polymixin B Membrane in Peritonitis With Septic Shock. http://clinicaltrials.gov/ct2/show/NCT01222663.
68. van Deuren M, Santman FW, van Dalen R, Sauerwein RW, Span LF, van der Meer JW. Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 1992;15:424-30.
69. Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002;30:1250-5.
70. Cole L, Bellomo R, Davenport P, Tipping P, Uchino S, Tetta C et al. The effect of coupled haemofiltration and adsorption on inflammatory cytokines in an ex vivo model. Nephrol Dial Transplant 2002;17:1950-6.
71. Formica M, Olivieri C, Livigni S, Cesano G, Vallero A, Maio M et al. Hemodynamic response to coupled plasmafiltration- adsorption in human septic shock. Intensive Care Med 2003;29:703-8.
72. Lentini P, Cruz D, Nalesso F, de Cal M, Bobek I, Garzotto F et al. A pilot study comparing pulse high volume hemofiltration (pHVHF) and coupled plasma filtration adsorption (CPFA) in septic shock patients. G Ital Nefrol 2009;26:695-703.
73. Mao HJ, Yu S, Yu XB, Zhang B, Zhang L, Xu XR et al. Effects of coupled plasma filtration adsorption on immune function of patients with multiple organ dysfunction syndrome. Int J Artif Organs 2009;32:31-8.
74. Haase M, Bellomo R, Morgera S, Baldwin I, Boyce N. High cut-off point membranes in septic acute renal failure: a systematic review. Int J Artif Organs 2007;30:1031-41.
75. Morgera S, Haase M, Rocktaschel J, Bohler T, von Heymann C, Vargas-Hein O et al. High permeability haemofiltration improves peripheral blood mononuclear cell proliferation in septic patients with acute renal failure. Nephrol Dial Transplant 2003;18:2570-6.
76. Morgera S, Haase M, Kuss T, Vargas-Hein O, Zuckermann-Becker H, Melzer C et al. Pilot study on the effects of high cutoff hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006;34:2099-104.
77. Honoré PM, Clark W: Preliminary results of the HICOSS study. Proc 10th WFSCICCM, Florence, Italy, 2009.
78. Haase M, Bellomo R, Baldwin I, Haase-Fielitz A, Fealy N, Davenport P et al. Hemodialysis membrane with a highmolecular- weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis 2007;50:296-304.
79. Lee D, Haase M, Haase-Fielitz A, Paizis K, Goehl H, Bellomo R: A pilot, randomized, double-blind, cross-over study of high cut-off versus highflux dialysis membranes. Blood Purif 2009;28:365-2.
80. Zhang P, Yang Y, Lv R, Zhang Y, Xie W, Chen J. Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: a singlecenter randomized clinical trial. Nephrol Dial Transplant 2012;27:967-73.
81. VA/NIH Acute Renal Failure Trial Network, Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D et al. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008;359:7-20.
82. RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009;361:1627-38.
83. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E; Hemofiltration and Sepsis Group of the Collège National de Réanimation et de Médecine d'Urgence des Hôpitaux extra-Universitaires. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009; 37:803-10.
84. Van Wert R, Friedrich JO, Scales DC, Wald R, Adhikari NK; University of Toronto Acute Kidney Injury Research Group. High-dose renal replacement therapy for acute kidney injury: Systematic review and meta-analysis. Crit Care Med 2010;38:1360-9.